New COPD inhaler shows promise in tiny pilot study

NCT ID NCT04087590

Terminated Symptom relief Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 pilot study tested a new dual bronchodilator inhaler called PT003 in 4 people with stable moderate-to-severe COPD. Researchers measured breathing patterns and lung function right after the first dose and again after 4 weeks of treatment. The goal was to see if PT003 could make breathing easier and more regular. Because the study was very small and terminated early, results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Formoterol-glycopyrronium (PT003) inhaler
What this could lead to: If it works, this could show that PT003 improves breathing patterns and reduces shortness of breath in people with moderate to severe COPD.
What could go wrong: This is a very small, early pilot study with only 4 participants, so results may not apply to everyone. The trial was terminated, so data may be incomplete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset Dyspnea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Show contact details

Locations

Hop Calmette Chu Lille

Lille, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.